---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-007393"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T04:32:08.356007+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics reports Q1 BRIUMVI net sales of $7.8M in first partial launch quarter

## Summary
- BRIUMVI net sales $7.8M for Q1 2023; over 400 prescriptions from 165+ HCPs at 125+ centers.
- Payor coverage in place for over 50% of covered lives; permanent J-code effective July 1, 2023.
- Net loss narrowed to $39.2M vs $69.0M YoY; cash $139.7M with $20M credit facility, funding into mid-2024.
- CHMP positive opinion for EU approval of BRIUMVI for RMS; additional data presented at ACTRIMS/AAN.
- R&D expense $15.9M (down from $48M) driven by lower manufacturing/clinical costs post-approval.

## SEC filing metadata
- accession: 0001558370-23-007393
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000155837023007393/0001558370-23-007393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000155837023007393/tgtx-20230501x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-007393
- JSON: https://secwatch.observer/filing/0001558370-23-007393.json
- Plain text: https://secwatch.observer/filing/0001558370-23-007393.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.